The spread of the new coronavirus (SARS-CoV-2) also poses a major challenge for clinical trials of medicinal products in Switzerland. 

Swissmedic and swissethics have therefore published a joint document ("Joint Guidance of Swissmedic and swissethics on the management of clinical trials with medicinal drug products in Switzerland during the COVID-19 pandemic"), which describes the most important recommendations for the treatment of patients in clinical trials of medicinal products. The document can be viewed on the respective Swissmedic and swissethics websites.